{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:01:46Z","timestamp":1768546906513,"version":"3.49.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[1998,6,16]]},"abstract":"<jats:p>\n            <jats:italic>Background<\/jats:italic>\n            \u2014Neutral endopeptidase (NEP) degrades vasoactive peptides, including the natriuretic peptides, angiotensin II, and endothelin-1. Systemic inhibition of NEP does not consistently lower blood pressure, even though it increases natriuretic peptide concentrations and causes natriuresis and diuresis. We therefore investigated the direct effects of local inhibition of NEP on forearm resistance vessel tone.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Methods and Results<\/jats:italic>\n            \u2014Four separate studies were performed, each with 90-minute drug infusions. In the first study, 10 healthy subjects received a brachial artery infusion of the NEP inhibitor candoxatrilat (125 nmol\/min), which caused a slowly progressive forearm vasoconstriction (12\u00b12%;\n            <jats:italic>P<\/jats:italic>\n            =0.001). In a second two-phase study, 6 healthy subjects received, 4 hours after enalapril (20 mg) or placebo, an intra-arterial infusion of the NEP inhibitor thiorphan (30 nmol\/min). Thiorphan caused similar degrees of local forearm vasoconstriction (\n            <jats:italic>P<\/jats:italic>\n            =0.6) after pretreatment with both placebo (13\u00b11%,\n            <jats:italic>P<\/jats:italic>\n            =0.006) and enalapril (17\u00b16%,\n            <jats:italic>P<\/jats:italic>\n            =0.05). In a third three-phase study, 8 healthy subjects received intra-arterial thiorphan (30 nmol\/min), the endothelin ET\n            <jats:sub>A<\/jats:sub>\n            antagonist BQ-123 (100 nmol\/min), and both combined. Thiorphan caused local forearm vasoconstriction (13\u00b11%,\n            <jats:italic>P<\/jats:italic>\n            =0.0001); BQ-123 caused local vasodilatation (33\u00b13%,\n            <jats:italic>P<\/jats:italic>\n            =0.0001). Combined thiorphan and BQ-123 caused vasodilatation (32\u00b11%,\n            <jats:italic>P<\/jats:italic>\n            =0.0001) similar to BQ-123 alone (\n            <jats:italic>P<\/jats:italic>\n            =0.98). In a fourth study, 6 hypertensive patients (blood pressure &gt;160\/100 mm Hg) received intra-arterial thiorphan (30 nmol\/min). Thiorphan caused a slowly progressive forearm vasoconstriction (10\u00b12%,\n            <jats:italic>P<\/jats:italic>\n            =0.0001).\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Conclusions<\/jats:italic>\n            \u2014Inhibition of local NEP causes vasoconstriction in forearm resistance vessels of both healthy volunteers and patients with hypertension. The lack of effect of ACE inhibition on the vasoconstriction produced by thiorphan and its absence during concomitant ET\n            <jats:sub>A<\/jats:sub>\n            receptor blockade suggest that it is mediated by endothelin-1 and not angiotensin II. These findings may help to explain the failure of systemic NEP inhibition to lower blood pressure.\n          <\/jats:p>","DOI":"10.1161\/01.cir.97.23.2323","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:41:02Z","timestamp":1339461662000},"page":"2323-2330","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":135,"title":["Inhibition of Neutral Endopeptidase Causes Vasoconstriction of Human Resistance Vessels In Vivo"],"prefix":"10.1161","volume":"97","author":[{"given":"Charles J.","family":"Ferro","sequence":"first","affiliation":[{"name":"From the Clinical Pharmacology Unit and Research Centre, University of Edinburgh, Western General Hospital, Edinburgh, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.","family":"Spratt","sequence":"additional","affiliation":[{"name":"From the Clinical Pharmacology Unit and Research Centre, University of Edinburgh, Western General Hospital, Edinburgh, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Haynes","sequence":"additional","affiliation":[{"name":"From the Clinical Pharmacology Unit and Research Centre, University of Edinburgh, Western General Hospital, Edinburgh, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Webb","sequence":"additional","affiliation":[{"name":"From the Clinical Pharmacology Unit and Research Centre, University of Edinburgh, Western General Hospital, Edinburgh, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.3.2.2521610"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2430183"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0820619"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2910083"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(84)90020-2"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(92)90303-R"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb16185.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(89)91682-3"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(90)90192-T"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.19.7580"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(81)90370-2"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6857267"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb05273.x"},{"key":"e_1_3_2_14_2","first-page":"R1011","volume":"254","year":"1988","unstructured":"Brands WM, Freedman RH. Aldosterone and renin inhibition by physiological levels of atrial natriuretic factor. Am J Physiol. 1988;254:R1011\u2013R1016.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6326267"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6944.1615"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90714-9"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199110000-00009"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199207000-00002"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.16.3.269"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0850019"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.26.6.1160"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.25.4.637"},{"key":"e_1_3_2_24_2","first-page":"307","volume":"336","year":"1990","unstructured":"Lefrancois P, Clerc G, Duchier J, Lim C, Lecomte JM, Gros C, Schwartz JC. Antihypertensive activity of sinorphan. Lancet. 1990;336:307\u2013308.","journal-title":"Lancet"},{"key":"e_1_3_2_25_2","first-page":"187","volume":"4","year":"1991","unstructured":"Sybertz EJ. SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator. Clin Nephrol. 1991;4:187\u2013191.","journal-title":"Clin Nephrol"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.22.1.119"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.22.2.231"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199304000-00011"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"Tunny TJ Ziesak MD Armstrong R Klemm SA Stowasser M Finn WL Gordon RD. Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension. J Hypertens. 1993;11(suppl 5):S222\u2013S223.","DOI":"10.1097\/00004872-199312050-00090"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/7.11.943"},{"key":"e_1_3_2_31_2","first-page":"351","volume":"48","year":"1995","unstructured":"Fettner SH, Pai S, Zhu G-R, Kosoglou T, Banfield CR, Batra V. Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metallopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension. Eur J Clin Pharmacol. 1995;48:351\u2013359.","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.18.6.798"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199203000-00011"},{"key":"e_1_3_2_34_2","first-page":"735","volume":"20","year":"1992","unstructured":"Richards AM, Crozier IG, Espiner EA, Ikram H, Yandle TG, Kosoglou T, Rallings M, Frampton C. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure. J Cardiovasc Pharmacol. 1992;20:735\u2013741.","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_3_2_35_2","first-page":"797","volume":"13","year":"1995","unstructured":"Favrat B, Burnier M, Nussberger J, Lecomte JM, Brouard R, Waeber B, Brunner HR. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens. 1995;13:797\u2013804.","journal-title":"J Hypertens"},{"key":"e_1_3_2_36_2","first-page":"118","volume":"335","year":"1990","unstructured":"Kahn JC, Patey M, Dubois-Rande JL, Merlet P, Castaigne A, Lim-Alexandre C, Lecomte JM, Duboc D, Gros C, Schwartz JC. Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet. 1990;335:118\u2013119.","journal-title":"Lancet"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92827-4"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.94.9.2131"},{"key":"e_1_3_2_39_2","first-page":"754","volume":"336","year":"1990","unstructured":"Barclay PL, Danilewicz JC, Samuels GMR. Inhibitory properties of UK-69 578 and thiorphan. Lancet. 1990;336:754\u2013755.","journal-title":"Lancet"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.16.5.564"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1159\/000159072"},{"key":"e_1_3_2_42_2","first-page":"303","volume":"1","year":"1988","unstructured":"Wiinberg N, Walter-Larson S, Eriksen C, Nielsen PE. An evaluation of semi-automatic blood pressure manometers against intra-arterial blood pressure. J Ambulatory Monitoring. 1988;1:303\u2013309.","journal-title":"J Ambulatory Monitoring"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb16669.x"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(80)90050-9"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0680483"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198704000-00015"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.85.2.1735147"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02576362"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1949.sp004348"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6719.230"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7044.1472"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","unstructured":"McMahon EG Palomo MA Moore WM. Phosphoramidon blocks the pressor activity of big endothelin-1 [1\u201339] and lowers blood pressure in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1989;17(suppl 7):S29\u2013S33.","DOI":"10.1097\/00005344-199100177-00009"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/0303-7207(89)90131-7"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1978.tb01595.x"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(91)90091-I"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.26.2.230"},{"key":"e_1_3_2_57_2","first-page":"F45","volume":"264","year":"1993","unstructured":"Dussaule J-C, Stefanski A, Bea M-L, Ronco P, Ardaillou R. Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol. 1993;264:F45\u2013F52.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_58_2","first-page":"H2033","volume":"257","year":"1989","unstructured":"Clarke JG, Benjamin N, Larkin SW, Webb DJ, Davies GJ, Maseri A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol. 1989;257:H2033\u2013H2035.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1986.tb02014.x"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb05357.x"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1987.tb13717.x"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(93)90450-H"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)41966-7"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(94)90120-1"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050196"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199209000-00023"},{"key":"e_1_3_2_67_2","unstructured":"Kugiyama K Sugiyama S Ohgushi M Matsumura T Yasue H. Suppression of atherosclerotic changes in cholesterol fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11; NEP). Circulation. 1993;88(suppl I):I-521 Abstract."},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(96)00101-5"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.CIR.97.23.2323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T16:56:11Z","timestamp":1715532971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.97.23.2323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6,16]]},"references-count":68,"journal-issue":{"issue":"23","published-print":{"date-parts":[[1998,6,16]]}},"alternative-id":["10.1161\/01.CIR.97.23.2323"],"URL":"https:\/\/doi.org\/10.1161\/01.cir.97.23.2323","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,6,16]]},"assertion":[{"value":"1997-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-02-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-06-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}